+
Site Tour

EuroEcho 2021: Advances to optimize tricuspid regurgitation management: the evidence

Maurizio Taramasso presents on the clinical and real-world outcomes from the TRILUMINATE trial and TriClip™ bRIGHT study, respectively.

Related Videos

Navitor™: Voice of the Experts Dave Smith

EACVI Summit 2023: Congress symposium

Review the Trends | Mitral focus

EuroPCR 2021: Advancing solutions for tricuspid regurgitation patients

AV VALVES 2023:Decision Making in HF – Mitral

Now you've got Navitor. Remarkable performance.

AV VALVES 2023: TR – Multileaflet Valve

Navitor™: Voice of the Experts Dave Smith

TRENDING TOPICS

EACTS 2024 - Novel approaches for Valvular and LVAD therapies

Reconsidering current approaches to valve and LVAD therapies

Early outcomes on Epic Max platform

Cleveland clinic (US) experience: Early outcomes and a perspective on porcine vs. bovine

Transfemoral TAVI

Navitor Vision 35 implantation

CONNEXT


HUB
RELATED RESOURCES

ESC 2021: HF & VHD Guidelines

EuroEcho 2021: Tricuspid regurgitation: The Patient

PCRLV 2022: bRIGHT 30 days

PCRLV 2022: bRIGHT 1 year

CONNEXT


LIVE
RELATED EVENTS

EuroPCR 2023: Vascular access

SAFETY IS A JOURNEY | M. Swaans & G. Leurent

AV VALVES 2023: The Genesis of TEER

TAVI Summit - TAVR in bicuspid

You are about to leave my-connext.com

You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

The content on this website is intended for healthcare professionals in EMEA with applicable health authority product registrations, excepted those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Click OK to confirm you are a healthcare professional to proceed.

OK Decline